Anti-MICA antibody case report
8 evidence topics · 1 source
Objective
Antibody monitoring objective
Location and study date
No evidence found.
Study design
Individual recipient report
Eligibility criteria
Not applicable.
Treatment
Treatment used after rejection
Study outcomes
Rationale for using Anti-MICA antibody reduction as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Reported participant
Description of analysis sets
Not applicable.
Results
Participant disposition
No evidence found.
Baseline characteristics
Baseline donor-specific antibodies
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
This report describes one recipient with preformed anti-MICA donor-specific antibodies. Antibody rebound occurred after 14 days, and early antibody-mediated rejection was reported. Later antibody removal followed immunoadsorption and daratumumab, so that outcome cannot be attributed to imlifidase alone.